Altimmune Inc
Altimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity and MASH.
Currently operating at a negative 244702.8% profit margin.
Current Price
$2.82
+8.46%GoodMoat Value
$0.00
99.9% overvaluedAltimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics.
The Company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity and MASH.
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Country
Maryland, USA
Altimmune Inc (ALT) is a Healthcare company in the Biotechnology industry. It trades on NASDAQ. The company is based in Maryland, USA.
Altimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity and MASH.
Market cap is $294.00M. There are 104.3M shares outstanding.
See the full Altimmune Inc profile on GoodMoat. It covers key officers, financial metrics, and sector details. You can also use GoodMoat's DCF calculator, fair value models, and quality score to help decide if ALT is a good investment.
